Abstract: Aim This study aimed at clinical comparative trial of sparf loxacin (SPLX)with lomef loxacin (LMLX).Methods Tw enty four patients with bacterial infections in respiratory tract or urinary tract wererandomly seperated to two groups of SPLX and LMLX.Af ter administration of 200 ~ 300 mg of SPLX once daily or 200 ~ 400 mg of LMLX twice daily, theclinical Effects were observed and defined as cure, obvious efficiency, effcativeness and no Effect.Results Isolation rate of bacteria from patients was 91.7 %.Total intake amount of SPLX was signi ficantly less than that of LM LX, but curerate and effectiverate in group SPLX were signi ficantly higher than in group LM LX.There were no adverse drugractions in both groups.Conclusions SPLXis a safe and effective drug among fluoroquinolones in treatment of bacterial infections.Theratio of Effect over dose of sparf loxacin is higher than that of lomefloxacin.

Key words: sparfloxacin, lomefloxacin, clinical trial